These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

344 related articles for article (PubMed ID: 21280078)

  • 1. Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab.
    Gunnarsson M; Malmeström C; Axelsson M; Sundström P; Dahle C; Vrethem M; Olsson T; Piehl F; Norgren N; Rosengren L; Svenningsson A; Lycke J
    Ann Neurol; 2011 Jan; 69(1):83-9. PubMed ID: 21280078
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination of CSF N-acetylaspartate and neurofilaments in multiple sclerosis.
    Teunissen CE; Iacobaeus E; Khademi M; Brundin L; Norgren N; Koel-Simmelink MJ; Schepens M; Bouwman F; Twaalfhoven HA; Blom HJ; Jakobs C; Dijkstra CD
    Neurology; 2009 Apr; 72(15):1322-9. PubMed ID: 19365053
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunosuppressive therapy reduces axonal damage in progressive multiple sclerosis.
    Axelsson M; Malmeström C; Gunnarsson M; Zetterberg H; Sundström P; Lycke J; Svenningsson A
    Mult Scler; 2014 Jan; 20(1):43-50. PubMed ID: 23702432
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protein biomarkers for multiple sclerosis: semi-quantitative analysis of cerebrospinal fluid candidate protein biomarkers in different forms of multiple sclerosis.
    Avsar T; Korkmaz D; Tütüncü M; Demirci NO; Saip S; Kamasak M; Siva A; Turanli ET
    Mult Scler; 2012 Aug; 18(8):1081-91. PubMed ID: 22252467
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neurofilament heavy chain in CSF correlates with relapses and disability in multiple sclerosis.
    Kuhle J; Leppert D; Petzold A; Regeniter A; Schindler C; Mehling M; Anthony DC; Kappos L; Lindberg RL
    Neurology; 2011 Apr; 76(14):1206-13. PubMed ID: 21346223
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CSF inflammation and axonal damage are increased and correlate in progressive multiple sclerosis.
    Romme Christensen J; Börnsen L; Khademi M; Olsson T; Jensen PE; Sørensen PS; Sellebjerg F
    Mult Scler; 2013 Jun; 19(7):877-84. PubMed ID: 23178691
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tau protein seems not to be a useful routine clinical marker of axonal damage in multiple sclerosis.
    Guimarães I; Cardoso MI; Sá MJ
    Mult Scler; 2006 Jun; 12(3):354-6. PubMed ID: 16764350
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Osteopontin concentrations are increased in cerebrospinal fluid during attacks of multiple sclerosis.
    Börnsen L; Khademi M; Olsson T; Sørensen PS; Sellebjerg F
    Mult Scler; 2011 Jan; 17(1):32-42. PubMed ID: 20921238
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multiple sclerosis: Biomarkers and genetic variants reflect disease course in multiple sclerosis.
    Wood H
    Nat Rev Neurol; 2016 Oct; 12(10):553. PubMed ID: 27615421
    [No Abstract]   [Full Text] [Related]  

  • 10. Natalizumab (Tysabri) treatment for relapsing multiple sclerosis.
    Johnson KP
    Neurologist; 2007 Jul; 13(4):182-7. PubMed ID: 17622909
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Severe relapses after the first infusion of natalizumab in active relapsing-remitting multiple sclerosis.
    Rinaldi F; Perini P; Calabrese M; Rinaldi L; Gallo P
    Mult Scler; 2009 Nov; 15(11):1359-62. PubMed ID: 19812116
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis.
    Rudick RA; Stuart WH; Calabresi PA; Confavreux C; Galetta SL; Radue EW; Lublin FD; Weinstock-Guttman B; Wynn DR; Lynn F; Panzara MA; Sandrock AW;
    N Engl J Med; 2006 Mar; 354(9):911-23. PubMed ID: 16510745
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cerebrospinal fluid biomarkers of β-amyloid metabolism in multiple sclerosis.
    Augutis K; Axelsson M; Portelius E; Brinkmalm G; Andreasson U; Gustavsson MK; Malmeström C; Lycke J; Blennow K; Zetterberg H; Mattsson N
    Mult Scler; 2013 Apr; 19(5):543-52. PubMed ID: 23069872
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glial and neuroaxonal biomarkers in a multiple sclerosis (MS) cohort.
    Kalatha T; Hatzifilippou E; Arnaoutoglou M; Balogiannis S; Koutsouraki E
    Hell J Nucl Med; 2019; 22 Suppl 2():113-121. PubMed ID: 31802051
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased cerebrospinal fluid levels of neurofilament protein in progressive supranuclear palsy and multiple-system atrophy compared with Parkinson's disease.
    Holmberg B; Rosengren L; Karlsson JE; Johnels B
    Mov Disord; 1998 Jan; 13(1):70-7. PubMed ID: 9452329
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tau protein in cerebrospinal fluid: a possible marker of poor outcome in patients with early relapsing-remitting multiple sclerosis.
    Martínez-Yélamos A; Saiz A; Bas J; Hernandez JJ; Graus F; Arbizu T
    Neurosci Lett; 2004 Jun; 363(1):14-7. PubMed ID: 15157986
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neurofilament light as a prognostic marker in multiple sclerosis.
    Salzer J; Svenningsson A; Sundström P
    Mult Scler; 2010 Mar; 16(3):287-92. PubMed ID: 20086018
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biomarkers of tau phosphorylation state are associated with the clinical course of multiple sclerosis.
    Emeršič A; Karikari TK; Kac PR; Gonzalez-Ortiz F; Dulewicz M; Ashton NJ; Brecl Jakob G; Horvat Ledinek A; Hanrieder J; Zetterberg H; Rot U; Čučnik S; Blennow K
    Mult Scler Relat Disord; 2024 Oct; 90():105801. PubMed ID: 39153429
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessing tissue damage in multiple sclerosis: a biomarker approach.
    Burman J; Zetterberg H; Fransson M; Loskog AS; Raininko R; Fagius J
    Acta Neurol Scand; 2014 Aug; 130(2):81-9. PubMed ID: 24571714
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Natalizumab treatment in multiple sclerosis: marked decline of chemokines and cytokines in cerebrospinal fluid.
    Mellergård J; Edström M; Vrethem M; Ernerudh J; Dahle C
    Mult Scler; 2010 Feb; 16(2):208-17. PubMed ID: 20007431
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.